CRVS News and Press, Corvus Pharmaceuticals Inc. From 02/19/21

Gainers: [[RNWK]] +14.1%. [[VIOT]] +8%. [[IMUX]] +7.5%. [[CRVS]] +6.4%. [[OTIC]] +4.4%.Losers: [[PT]] -4.7%. [[OBSV]] -2.8%. [[PETS]] -2.6%. [[EVGN]] -2%. [[EOLS]] -1.7%. For further details see: PETS, IMUX, EVGN and OTIC among after-hours movers

Corvus Pharmaceuticals (CRVS) is surging with a ~5.9% gain in the post-market after regulatory filing indicated the share purchases by the insider Orbimed Advisors.In what could the largest insider purchase of shares in the company’s recent history, the entity has a...

Corvus Pharmaceuticals (CRVS) has completed a previously announced public offering of 8,571,429 shares of common stock.Underwriters' options includes another 1,212,231 shares.Shares were priced at $3.50 per share.Gross proceeds from offering were $34.2M, with net proceeds of $31.8M.Corvus sha...

BURLINGAME, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced the completion of its previously announced underwritten public offering of 9,783,660 shares of its common stock, which includes 1,212...

Corvus Pharmaceuticals (CRVS) prices its underwritten public offering of 8.57M shares at $3.50/share, with gross proceeds expected to be $30M.The company has granted underwriters a 30-day option to purchase up to an additional 1.3M shares. The offering is expected to close on or about Fe...

BURLINGAME, Calif., Feb. 12, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering of 8,571,429 shares of its common stock at a price to the public of $3.50 per share, f...

Gainers: [[HX]] +16.9%. [[ASYS]] +11.8%. [[TWOU]] +8.2%. [[VITL]] +7.1%. [[OGI]] +6.3%.Losers: [[FOLD]] -19.6%. [[LLNW]] -15.5%. [[SVMK]] -13%. [[AFRM]] -8.5%. [[CRVS]] -7.4%. For further details see: OGI, TWOU, FOLD and LLNW among after-hours movers

Corvus Pharma (CRVS) announces that it has commenced an underwritten public offering of its shares.It expects to grant the underwriters a 30-day option to purchase up to an additional 15% of shares.The company said it currently expects to use net proceeds to fund its Phase 3 clinical trial of...

BURLINGAME, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares to be sold in the offering wil...

Corvus Pharmaceuticals ([[CRVS]] -8.2%) is set to reverse the double-digit gain recorded yesterday after Mizuho Securities downgraded the stock to neutral from buy citing the company’s recent efforts to reposition the pipeline.The analyst Mara Goldstein and the team note that the compa...